Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Jianming Guo
Observed name:
Guo, Jianming
Institutions:
Shanghai Medical College of Fudan University,
Fudan University,
Zhongshan Hospital
Observed institutions:
Shanghai Medical College of Fudan University,
Fudan University,
China North Industries Group Corporation (China),
Zhongshan Hospital,
Zhejiang University of Finance and Economics
ORCID:
0009-0009-6535-9317
Observed ORCID:
0009-0009-6535-9317
OpenAlex ID:
A5104077518
Allocation of emission allowances considering strategic voting
2022
·
Tianhua Mei
, Jie Liu
, et al.
·
Energy Economics
·
8
Fruquintinib plus serplulimab as first-line therapy in metastatic or unresectable non-clear cell renal cell carcinoma (nccRCC): Updated efficacy and safety data from a multicenter, single-arm, phase II trial.
2026
·
Jiwei Huang
, Xiaoyi Hu
, et al.
·
Journal of Clinical Oncology
·
1
PDF
IL-15RαFc superagonist SHR-1501 with or without bacille Calmette Guerin (BCG) for high-risk non-muscle invasive bladder cancer (NMIBC): A phase 1/2 study.
2025
·
Yuke Chen
, Hailong Hu
, et al.
·
Journal of Clinical Oncology
·
1
Updated results from a phase I/II study of CBP-1018, a bi-ligand–drug conjugate (Bi-XDC) as late line therapy for patients with metastatic castration resistant prostate cancer (mCRPC).
2025
·
Kaiwen Li
, Jianming Guo
, et al.
·
Journal of Clinical Oncology
·
1
Analysis of the application prospect of artificial intelligence in the field of aviation munitions
2023
·
Jianming Guo
, Zhidan Zhang
, et al.
·
International Conference on Computer, Artificial Intelligence and Control Engineering (CAICE)
·
1
Retraction: Senescent Stromal Cells Promote Cancer Resistance through SIRT1 Loss-Potentiated Overproduction of Small Extracellular Vesicles
2026
·
Liu Han
, Qilai Long
, et al.
·
Cancer Research
PDF
A phase II study evaluating pharmacokinetics and dosimetry of 177Lu-PSMA-617 radioligand therapy in Chinese participants with progressive metastatic castration-resistant prostate cancer
2026
·
Hongcheng Shi
, Jianming Guo
, et al.
·
EJNMMI Research
The efficacy and safety of 177 Lu-PSMA-617 in Chinese patients with post-taxane metastatic castration-resistant prostate cancer: From a multicenter phase II study.
2026
·
Dingwei Ye
, Shaoli Song
, et al.
·
Journal of Clinical Oncology
PDF
Pharmacokinetics and Dosimetry of [ 68 Ga]Ga-PSMA-11 in Chinese Participants with Progressive Metastatic Castration-Resistant Prostate Cancer: A Phase 2 Study
2026
·
Wei Fan
, Yonghong Li
, et al.
·
Cancer Biotherapy and Radiopharmaceuticals
Hexaminolevulinate blue light cystoscopy improves bladder cancer detection in comparison to white light cystoscopy: a prospective, comparative, within-patient controlled multicenter phase III bridging study in China
2026
·
Hailong Hu
, Jian Huang
, et al.
·
Frontiers in Urology
PDF
Supplementary Data from Senescent Stromal Cells Promote Cancer Resistance through SIRT1 Loss-Potentiated Overproduction of Small Extracellular Vesicles
2023
·
Liu Han
, Qilai Long
, et al.
Additional file 1: Table S1. of Low CCL17 expression associates with unfavorable postoperative prognosis of patients with clear cell renal cell carcinoma
2017
·
Xiong, Ying
, Liu, Li
, et al.
·
Figshare
Show more works
View as search
Works count:
12
Citation count:
12
H-index:
1
I10-index:
Year
Topic
Type